DCM
VIVO

Delpha Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

Delpha Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-882
Closed -$12K – 1382
2017
Q4 		$12K Buy
+882
New +$12.9K 0.01% 1014

Other funds holding VIVO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
PP
Prudential plc London, England, United Kingdom $18.4B AUM 23.98% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $5.02B AUM 66.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Delpha Capital Management's VIVO Position: Q1 2018 in Review

Delpha Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q1 2018, closing a stake of 882 shares — an estimated $12K sold.

Delpha Capital Management first reported a position in VIVO in Q4 2017 and held it in 1 quarter. The position peaked at $12K in Q4 2017. 186 funds tracked by Wall St. Rank hold VIVO as of Q1 2018.

  • Delpha Capital Management reported no remaining Meridian Bioscience Inc position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 882 Meridian Bioscience Inc shares in Q1 2018, an estimated $12K.
  • Delpha Capital Management first reported a position in Meridian Bioscience Inc in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Meridian Bioscience Inc position peaked at $12K in Q4 2017.
  • 186 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.